Hib-DTaP-poliovirus vaccine - KM Biologics
Alternative Names: KD-370Latest Information Update: 31 Dec 2024
At a glance
- Originator Kaketsuken
- Developer KM Biologics
- Class Bacterial vaccines; Haemophilus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 31 Dec 2024 Launched for Diphtheria (In children, In infants, Prevention) in Japan (SC) before December 2024 (Meiji Seika Pharma pipeline, December 2024)
- 31 Dec 2024 Launched for Haemophilus infections (In children, In infants, Prevention) in Japan (SC) before December 2024 (Meiji Seika Pharma pipeline, December 2024)
- 31 Dec 2024 Launched for Pertussis (In children, In infants, Prevention) in Japan (SC) before December 2024 (Meiji Seika Pharma pipeline, December 2024)